UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Identify the mix that offers broader exposure for retirement by comparing Sp500 and total market allocations and adjusting for risk.
28,595 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
CME Group announced it will file a lawsuit against the CFTC after the regulator approved Bitcoin perpetual futures in...
As investment pours into Grand Rapids, the city could become a regional magnet for jobs, housing, and business growth...
When a fund sells a big stake in Champion Homes, it can reveal more about market sentiment than a quarterly report. T...
One transportation stock could outpace the S&P 500 in 2026 thanks to rising freight volumes, pricing power, and stron...
A major partnership reshapes Novo Nordisk's growth trajectory. This deep dive explains what the Vivtex deal means for...
When archer aviation stock plummeted, traders searched for the root causes. This guide breaks down the catalysts, inc...
The United States faces a thinner fiscal buffer as debt climbs to $39 trillion, now taller than annual GDP. A top eco...
Nipsey Hussle’s children have now received half of their father’s estate after a lengthy probate. This article explai...
A multi-decade rally faces a valuation crossroads as the CAPE gauge sits near historic highs. Here’s how years market...
Brookfield is quietly expanding its private debt platform, aiming to become a major player in private credit. This ar...
A Trump-themed memecoin crash leaves close to a million holders deep in losses, even as the president discloses hefty...